gallbladder tirzepatide Can You Take Weight Loss Medication If You Have Disease? Does GLP-1 Cause Gallbladder Problems?

You're always wondering, you're always wanting to know, you're wanting to do the best

In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: 3Q 2025 the first GLP-1 (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction 4Q 2025 Wegovy for heart failure with preserved ejection fraction and obesity October 2025 new indication for oral Rybelsus for secondary CV risk reduction 2025 Ozempic for T2DM and peripheral artery disease (PAD) Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape

The increased gallstone risk appears to be associated with several factors: Altered bile composition due to rapid fat metabolism Increased cholesterol saturation in bile Changes in gallbladder function during weight loss Patients should be aware that these risks are not unique to weight loss injections any method of rapid weight loss, including very low-calorie diets or bariatric surgery, carries similar gallstone-related risks

In the standing position, due to gravity (9.8 m/s), the abdominal fat pad undergoes downward physical displacement